THE CENTRAL AND EASTERN EUROPEAN TRAINING COURSE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

24-28 SEPTEMBER 2018,

MINSK, BELARUS

EVALUATION OF THE WORKSHOP

Galina Mozgova
Head of the National Coordination Biosafety Centre,
Institute of Genetics and Cytology of the National Academy of Sciences of Belarus

http://www.biosafety.by/

RA/ General principles
Annex III of the Cartagena Protocol

Risk assessment should be carried out in a scientifically sound and transparent manner, and can take into account expert advice of, and guidelines developed by, relevant international organizations.
Lack of scientific knowledge or scientific consensus should not necessarily be interpreted as indicating a particular level of risk, an absence of risk, or an acceptable risk.
Risks associated with living modified organisms or products thereof, namely, processed materials that are of living modified organism origin, containing detectable novel combinations of replicable genetic material obtained through the use of modern biotechnology, should be considered in the context of the risks posed by the non-modified recipients or parental organisms in the likely potential receiving environment.
Risk assessment should be carried out on a case-by-case basis. The required information may vary in nature and level of detail from case to case, depending on the living modified organism concerned, its intended use and the likely potential receiving environment.

RA/ General principles Annex III of the Cartagena Protocol

To fulfil its objective, risk assessment entails, as appropriate, the following steps:

(a)

An identification of any novel genotypic and phenotypic characteristics associated with the living modified organism that may have adverse effects on biological diversity in the likely potential receiving environment, taking also into account risks to human health;

(b)

An evaluation of the likelihood of these adverse effects being realized, taking into account the level and kind of exposure of the likely potential receiving environment to the living modified organism;

(c)

An evaluation of the consequences should these adverse effects be realized;

(d)

An estimation of the overall risk posed by the living modified organism based on the evaluation of the likelihood and consequences of the identified adverse effects being realized;

(e)

A recommendation as to whether or not the risks are acceptable or manageable, including, where necessary, identification of strategies to manage these risks; and

(f)

Where there is uncertainty regarding the level of risk, it may be addressed by requesting further information on the specific issues of concern or by implementing appropriate risk management strategies and/or monitoring the living modified organism in the receiving environment.

THE ROADMAP FOR RISK ASSESSMENT



COLLABORATION OF ALL RELEVANT ORGANIZATIONS IN RA IN COUNTRY AND REGIONAL LEVELS

MANY THANKS TO ALL OF YOU!!!

WE LEARNED A LOT FROM YOU!!!